|style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers|
|SMILES||Script error: No such module "collapsible list".|
|style="background: #F8EABA; text-align: center;" colspan="2" | Properties|
|Molar mass||461.46 g/mol|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)|
Morphine-6-glucuronide (M6G) is a major active metabolite of morphine, and as such is the molecule responsible for much of the pain-relieving effects of morphine (and thus heroin and codeine). This analgesic activity of M6G (in animals) was first noted by Yoshimura.
Subsequent work at St Bartholomew's Hospital, London in the 1980s, using a sensitive and specific HPLC assay, accurately defined for the first time the metabolism of morphine, and the abundance of this metabolite (along with morphine-3-glucuronide and morphine-3,6-diglucuronide, both considered inactive metabolites).
It was postulated that renal impairment would result in accumulation of the renally-excreted active agent M6G, leading to potentially fatal toxicity such as respiratory depression. The frequent use of morphine in critically ill patients, and the common occurrence of renal failure in this group implied that M6G accumulation could be a common, but previously unanticipated problem. The first studies demonstrated massive levels of M6G in 3 patients with renal failure, which resolved as kidney function returned. Subsequent work formally examined the role of renal function in the pharmacokinetics of morphine and its metabolites by studying their behaviour before and after renal transplantation.
A key step in defining the importance of M6G in man came in 1992 when the substance was artificially synthesised and administered to patients with pain, the majority of whom described pain relief.
The mu-3 receptor substype is further evidenced to be activated (agonized) by morphine-6β-glucuronide but not morphine itself. This finding is also true of certain heroin metabolites (6-MAM) but not morphine proper.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- Hidetoshi, Y; Oguri, K; Tsukamoto, H (1969). "Metabolism of drugs. LXII. Isolation and identification of morphine glucuronides in urine and bile of rabbits". Biochem Pharmacol. 18 (2): 279–86. doi:10.1016/0006-2952(69)90205-6. PMID 5778147.
- Osborne, R; Joel, S; Trew, D; Slevin, M (1990). "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide". Clin Pharmacol Ther. 47 (1): 12–9. doi:10.1038/clpt.1990.2. PMID 2295214.
- Joel, S; Osborne, RJ; Slevin, ML (1988). "An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites". J Chromatogr. 430 (2): 394–9. doi:10.1016/S0378-4347(00)83176-X. PMID 3235512.
- Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. JT Van Crugten, BC Sallustio, RL Nation and AA Somogyi. Department of Clinical and Experimental Pharmacology, University of Adelaide, Australia.
- Osborne, R J; Joel, SP; Slevin, ML (1986). "Morphine intoxication in renal failure: the role of morphine-6-glucuronide". Br Med J. 292 (6535): 1548–9. doi:10.1136/bmj.292.6535.1548. PMC . PMID 3087512.
- Osborne, R; Joel, S; Grebenik, K; Trew, D; Slevin, M (1993). "The pharmacokinetics of morphine and morphine glucuronides in kidney failure". Clin Pharmacol Ther. 54 (2): 158–67. doi:10.1038/clpt.1993.127. PMID 8354025.
- Osborne, R; Thompson, P; Joel, S; Trew, D; Patel, N; Slevin, M (1992). "The analgesic activity of morphine-6-glucuronide". Br J Clin Pharmacol. 34 (2): 130–8. PMC . PMID 1419474.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.